Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06125652
PHASE1/PHASE2
Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)
Sponsor: Xuzhou Medical University
View on ClinicalTrials.gov
Summary
To evaluate the safety and efficacy of anti Tim3/CD123 CAR-T cells in the treatment of relapsed and refractory acute myeloid leukemia.
Official title: Application of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2023-11-04
Completion Date
2027-01-01
Last Updated
2023-11-09
Healthy Volunteers
No
Interventions
DRUG
anti Tim-3/CD123 CAR-T cell therapy
Enrolled patients will receive prespecified dose of autologous CAR-T cells.
Locations (1)
Kailin Xu
Xuzhou, Jiangsu, China